image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Alliance Pharma - Substantial eps enhancing acquisition

March 2010

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 29p
For the second time in two months, forecasts have been raised significantly, triggering a surge in the shares to a new high of 30.25p. The catalyst was Alliance Pharma's eps enhancing acquisition of 18 generic drugs for between £14.3m and £16.4m from privately owned Cambridge Laboratories, which is being funded through a combination of a £7.5m vendor placing at 26p and a £4m increase in its term loan, plus an extra £1m working capital facility.The 18 medicines, which generate £10.6m sales, include three widely used cancer drugs including, ImmuCyst, a BCG immunotherapy for bladder tumours; Procarbazine (chemotherapy for Hodgkin's lymphoma); and Gelclair, a protective gel for the oral mucositis caused by chemotherapy. These th ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Alliance Pharma (July 2013)
Alliance Pharma - Acquires new products (September 2012)
Alliance Pharma (June 2012)
Alliance Pharma (November 2011)
Alliance Pharma - Cambridge Labs nehind its growth (June 2011)
Alliance Pharma (October 2010)
Alliance Pharma (August 2010)
Alliance Pharma - Trading ahead of expectations (July 2010)
Alliance Pharma - Gain reaches 75% in five months (May 2010)
Alliance Pharma - Beats expectations again (February 2010)
Alliance Pharma - Branded pharmaceuticals firm going great guns but cheap on PE of 6.7 (December 2009)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X